New Markers To Make Better Treatment Decisions For Prostate Cancer

Making treatment decisions once you have been diagnosed with prostate cancer is difficult. Often, it is impossible to accurately and reliably be able to predict the eventual course of the cancer. Prostate cancer, besides being one of the slower growing cancers, is also one of the deadliest. So good, informed decisions are vital. The original standby prognostic markers for prostate cancer are a man’s PSA, the stage of the cancer and their Gleason grade. Given the poor quality of these markers, in the 2000s, more sensitive markers were developed, such as PSA density, % of positive cores, % of cancer [...]

How To Get A Blood Test For AR-V7 If You Have Castrate Resistant Prostate Cancer

In the near future we should be seeing more non-invasive methods to evaluate if a man is responding to their drugs. One such example is the blood bio-marker available only at Johns Hopkins, the Androgen Receptor Variant 7 (AR-V7). Evaluating the presence of the antibody AR-V7 in the blood strongly indicates whether or not both abiraterone acetate (Zytiga) and enzalutamide (Xtandi) are demonstrating efficacy (working). The hitch is that this blood test is available only at Johns Hopkins in Baltimore, Maryland. If you are trying to determine if your enzalutamide or abiraterone is working by having this test you can [...]